Alphabet in July, after serving as CFO at pharmaceutical company Eli Lilly for three years. At a tech conference earlier this ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

One of the highlights of Eli Lilly's third-quarter results ... with fewer than 10% switching from Trulicity, said Lilly's chief financial officer Anat Ashkenazi on the call. Now, Lilly's focus ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Adjoa Andoh, Evangeline Lilly and Giorgio Moroder are set for tributes at the new Italian Global Series TV Festival that will ...

5:16 PM UTC Eli Lilly plans to launch weight-loss drug in emerging markets this year Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India ...